These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3804373)

  • 1. Lipopolysaccharides as complement inhibitors by complex formation with the purified third complement component (C3).
    Beuscher HU; Brade V
    Immunobiology; 1986 Oct; 173(1):41-55. PubMed ID: 3804373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretranslational regulation of the synthesis of the third component of complement in human mononuclear phagocytes by the lipid A portion of lipopolysaccharide.
    Strunk RC; Whitehead AS; Cole FS
    J Clin Invest; 1985 Sep; 76(3):985-90. PubMed ID: 3900137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Haemophilus influenzae type b lipopolysaccharide on complement activation and polymorphonuclear leukocyte function.
    Inzana TJ; Tosi MF; Kaplan SL; Anderson DC; Mason EO; Williams RP
    Pediatr Res; 1987 Dec; 22(6):659-66. PubMed ID: 3324033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of lipopolysaccharides and of lipid A from Yersinia enterocolitica with purified guinea pig C3.
    Brade V; Kreuzpaintner G
    Immunobiology; 1980 Jan; 156(4-5):441-53. PubMed ID: 7372350
    [No Abstract]   [Full Text] [Related]  

  • 5. A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4.
    Joiner KA; Goldman R; Schmetz M; Berger M; Hammer CH; Frank MM; Leive L
    J Immunol; 1984 Jan; 132(1):369-75. PubMed ID: 6197449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the synthesis of the third component of complement and factor B in cord blood monocytes by lipopolysaccharide.
    Sutton MB; Strunk RC; Cole FS
    J Immunol; 1986 Feb; 136(4):1366-72. PubMed ID: 3003195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human complement activation by smooth and rough Proteus mirabilis lipopolysaccharides.
    Kaca W; Arabski M; Fudała R; Holmström E; Sjöholm A; Weintraub A; Futoma-Kołoch B; Bugla-Płoskońska G; Doroszkiewicz W
    Arch Immunol Ther Exp (Warsz); 2009; 57(5):383-91. PubMed ID: 19707721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus.
    Rus HG; Kim LM; Niculescu FI; Shin ML
    J Immunol; 1992 Feb; 148(3):928-33. PubMed ID: 1530957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo.
    Joiner KA; Grossman N; Schmetz M; Leive L
    J Immunol; 1986 Jan; 136(2):710-5. PubMed ID: 2416822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Homeostasis of the complement system--complement inhibitors].
    Nagaki K
    Nihon Rinsho; 1979 May; 37(5):969-76. PubMed ID: 381728
    [No Abstract]   [Full Text] [Related]  

  • 15. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete absence of the third component of complement in man.
    Ballow M; Shira JE; Harden L; Yang SY; Day NK
    J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria.
    Mejia P; Davis AE
    Shock; 2012 Aug; 38(2):220-5. PubMed ID: 22576004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructure of lipopolysaccharides of Yersinia enterocolitica, Salmonella typhimurium and Escherichia coli.
    Acker G; Wartenberg K
    Zentralbl Bakteriol Orig A; 1976 Aug; 235(4):439-52. PubMed ID: 185850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lipopolysaccharide on C3 and C5 production by human lung cells.
    Rothman BL; Merrow M; Despins A; Kennedy T; Kreutzer DL
    J Immunol; 1989 Jul; 143(1):196-202. PubMed ID: 2732467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.